Search company, investor...

Zosano Pharma

Founded Year



Asset Sale | AssetsPurchased

Total Raised




About Zosano Pharma

Zosano Pharma (NASDAQ: ZSAN) operates as a clinical-stage biopharmaceutical company. It helps in the systemic administration of therapeutics and other bioactive molecules to patients by using its intracutaneous microneedle patch system. It develops a paradigm for delivering molecules where the inconvenience and pain are associated with subcutaneous, intravenous, or other complex administrations. It was formerly known as Macroflux. Zosano Pharma was founded in 2006 and is based in Fremont, California.

Headquarters Location

34790 Ardentech Court

Fremont, California, 94555,

United States


Missing: Zosano Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Zosano Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Zosano Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zosano Pharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Zosano Pharma Patents

Zosano Pharma has filed 6 patents.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Piperazines
  • Piperidines
patents chart

Application Date

Grant Date


Related Topics




Serotonin receptor agonists, Piperidines, Piperazines, Fluoroarenes, Amines


Application Date


Grant Date



Related Topics

Serotonin receptor agonists, Piperidines, Piperazines, Fluoroarenes, Amines



Latest Zosano Pharma News

Cluster Headache Market to See Booming Worldwide 2023-2030 | Zosano Pharma, Eli Lilly and Company, Lundbeck

May 11, 2023

| Zosano Pharma, Eli Lilly and Company, Lundbeck News Provided By Share This Article Cluster Headache develop a management plan, and monitor the condition to improve the individual's well-being and quality of life. The global cluster headache market is estimated to be valued at US$ 355.2 Million in 2023 and is expected to increase to US$ 550.1 Million by 2030, witnessing a CAGR of 6.4%” — Coherent Market Insights BURLINGAME, CALIFORNIA, UNITED STATES, May 11, 2023 / / -- The global Cluster Headache market size is expected to reach USD 550.1 million by 2030, registering a CAGR of 6.4% from 2023 to 2030, according to a new report by Coherent Market Insights Inc. Cluster headache (CH) is a rare form of headache characterized by intense, excruciating pain that occurs in recurrent episodes known as clusters. These attacks typically last between 15 minutes and three hours, and they can happen daily or almost daily for weeks or months. The causes of cluster headache are thought to be associated with the sudden release of histamine or serotonin in the area of a facial nerve called the trigeminal nerve, possibly influenced by the hypothalamus, a small area at the base of the brain. Various triggers can initiate cluster headache episodes, including alcohol consumption, cigarette smoking, high altitudes, bright lights, exertion, heat, foods rich in nitrite, certain medications, and cocaine. Cluster headache aims to alleviate pain during an attack, shorten the duration of the cluster period, and prevent future clusters. Acute treatments include oxygen therapy, triptans, and certain medications targeting the calcium channels. Preventive treatments involve medications to reduce the frequency and intensity of cluster headache episodes. Cluster headache can significantly impact a person's quality of life. Supportive measures, such as stress management techniques, maintaining a regular sleep schedule, avoiding triggers, and seeking support from healthcare professionals or support groups, can help individuals cope with the condition. Request for Sample Copy with Complete TOC and Figures & Graphs @ Key Highlights of the Report: • Market Size and Growth Potential • Dynamics & Investment Opportunities Latest Industry Trends and Developments: The report highlights challenging areas of the market, such as industry saturation, changing consumer preferences, and regulatory hurdles. It also covers recent technological developments in the Cluster Headache Market and their impact on the industry, offering a more comprehensive understanding. Furthermore, the report addresses drivers, constraints, and current issues such as regulatory changes and supply chain disruptions. It also provides insights into growth opportunities, indicating areas of the market with potential for expansion or development. Exploring Competitive Landscape: The report covers various aspects of key companies in the Cluster Headache Market, including their market share, revenue, production, sales, gross margin, price, manufacturing base, and product applications. It evaluates the competition between these companies and how they utilize strategies such as mergers & acquisitions, collaboration, partnership, and product launches to maintain or enhance their market share. Summary and Implications: In conclusion, this report provides a comprehensive and detailed analysis of the global Cluster Headache Market, offering valuable insights to a broad spectrum of industry stakeholders and facilitating strategic decision-making processes. The regional analysis showcases product/service usage and factors influencing the market in each region. This helps businesses identify opportunities and challenges in different regions, facilitating informed decisions regarding expansion, product development, and pricing strategies. We Offer Customized Report, Click @ North America (United States, Canada, and Mexico) Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia) South America (Brazil, Argentina, Colombia Global Cluster Headache Market 2023 Key Insights: This report presents a thorough research and analysis of the current state and future forecast of the Cluster Headache Market. It covers important aspects such as production, price structure, consumption, and historical data. The report provides a comprehensive understanding of the structure of the Cluster Headache Market industry by identifying its various segments and sub-segments. Market analysis includes a breakdown of data by company, products, end-users, and major countries. It encompasses historical data from 2017 to 2022 and provides a forecast up to 2030. The report analyzes the individual growth trends, future prospects, and contributions of each segment to the overall Cluster Headache Market. Furthermore, it examines competitive expansions such as agreements, new product launches, and acquisitions in the market. Key international players in the Cluster Headache Market are evaluated to assess their sales volume, revenue, growth potential, drivers, SWOT analysis, and future development plans. In summary, this report offers a comprehensive analysis of the Cluster Headache Market, including production, consumption, historical data, segmentation, competitive expansions, and strategies of key market players. Highlights of the Global Cluster Headache Market Report: The analysis provides a comprehensive examination of the global Cluster Headache Market, including market size (in US$ million) and compound annual growth rate (CAGR%) for the forecast period of 2023-2030, with 2021 as the base year. The report presents enticing investment proposition matrices for the Cluster Headache Market, outlining the potential future growth of key revenue streams. It offers valuable insights into market forces, limitations, opportunities, new product introductions or approvals, market trends, regional perspectives, and competitive strategies employed by top rivals. Key players in the global Cluster Headache Market are covered, highlighting factors such as company highlights, product portfolio, significant achievements, financial performance, and strategies. The insights derived from this research will enable marketers and company leaders to make informed decisions regarding upcoming product launches, type updates, market expansion, and marketing strategies. The global Cluster Headache Market research encompasses a wide range of industry stakeholders, including investors, vendors, product manufacturers, distributors, new entrants, and financial analysts. The various strategy matrices employed in researching the global Cluster Headache Market will assist stakeholders in making informed decisions. Purchase This Premium Research Report: Check out more related studies published by Coherent Market Insights Inc India immune oncology drugs market - India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2023 and is expected to exhibit a CAGR of 13.1% during the forecast period (2023 -2030). Tissue glue and bio adhesive sealants market - The global tissue glue and bio-adhesive sealants market is estimated to be valued at US$ 2,007.6 million in 2023 and is expected to exhibit a CAGR of 8.1% between 2023 and 2030. North america toxicology laboratories market - North America toxicology laboratories market is estimated to be valued at US$ 271.0 Million in 2023, exhibiting a CAGR of 4.1% during the forecast period (2023-2030). Mr.Shah

Zosano Pharma Frequently Asked Questions (FAQ)

  • When was Zosano Pharma founded?

    Zosano Pharma was founded in 2006.

  • Where is Zosano Pharma's headquarters?

    Zosano Pharma's headquarters is located at 34790 Ardentech Court, Fremont.

  • What is Zosano Pharma's latest funding round?

    Zosano Pharma's latest funding round is Asset Sale.

  • How much did Zosano Pharma raise?

    Zosano Pharma raised a total of $109.23M.

  • Who are the investors of Zosano Pharma?

    Investors of Zosano Pharma include Emergex, Eli Lilly and Company, New Enterprise Associates, BioMed Realty Ventures, Phase4 Ventures and 5 more.

  • Who are Zosano Pharma's competitors?

    Competitors of Zosano Pharma include Horizon Therapeutics, Radius, Prevtec Microbia, Intarcia Therapeutics, BioCardia, Alexza Pharmaceuticals, NeurOP, NuPathe, Santarus, Acton Pharmaceuticals and 19 more.

Compare Zosano Pharma to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


SoluBest is a clinical stage pharmaceutical company developing nanoformulations of existing therapeutic medicines in several fields. Solubest uses its advanced polymer formulations to prepare nano-particles of drugs with delivery or compliance insufficiencies. SoluBest's pipeline of existing off-patent drugs are being re-formulated for:nn * its own product developmentn * co-development partners

Banyan Biomarkers Logo
Banyan Biomarkers

Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics

United Biomedical

United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.